Edgar Filing: Regulus Therapeutics Inc. - Form 4

Regulus Th Form 4	nerapeutics Inc.									
February 2	3, 2017									
FOR	M 4	~~							PPROVAL	
Washington, D.C. 20549								OMB Number:	3235-0287	
Check 1 if no lo subject Section Form 4 Form 5 obligati	to 16. or Filed put	rsuant to S	Washington, D.C. 20549 OF CHANGES IN BENEFICIAL OV SECURITIES Section 16(a) of the Securities Exchan				nge Act of 1934,	Expires: Estimated burden ho response.	urs per	
may co <i>See</i> Ins 1(b).	ntinue. truction			•	•	mpany Act ny Act of 1	of 1935 or Section 940	on		
(Print or Type	e Responses)									
1. Name and Address of Reporting Person <u>*</u> Hagan Joseph P			2. Issuer Name and Ticker or Trading Symbol Regulus Therapeutics Inc. [RGLS				5. Relationship of Reporting Person(s) to Issuer			
(Last)	(First) (Middle) 3. Date of Earliest Tr			ransaction		(Check all applicable)				
C/O REGU INC., 106 DRIVE	(Month/Day/Year) 02/15/2017				Director 10% Owner X Officer (give title Other (specify below) below) below) Chief Operating Officer					
(Street) 4. If Amendme Filed(Month/Da					th/Day/Year) Applicable Line)		oint/Group Filing(Check One Reporting Person			
SAN DIE	GO, CA 92121							More than One R		
(City)	(State)	(Zip)	Tat	ole I - Non-J	Derivative	Securities A	Acquired, Disposed of	of, or Beneficia	ally Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution any	Date, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3,	(A) or of (D)	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Re	eport on a separate line	e for each cl	ass of sec	urities bene	ficially ow	ned directly	or indirectly.			
					inforı requi	nation cont red to respo ays a curre	spond to the collectained in this form ond unless the for ntly valid OMB co	are not rm	SEC 1474 (9-02)	
	Tab					sposed of, or convertible	Beneficially Owned securities)	I		
		saction Date /Day/Year)			4. Transact	5. Number iorDerivative			7. Title and Amount of Underlying Securities	

Edgar Filing: Regulus Therapeutics Inc. - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8	Securities Acquired (A Disposed o (Instr. 3, 4, 5)	f (D)	(Month/Day/Year)		(Instr. 3 and 4)	
				Code	7 (A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 1.2	02/15/2017		А	160,000		<u>(1)</u>	02/14/2027	Common Stock	160,000

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Hagan Joseph P C/O REGULUS THERAPEUTICS INC. 10614 SCIENCE CENTER DRIVE SAN DIEGO, CA 92121			Chief Operating Officer				
Signatures							
Christopher Aker, Attorney in Fact	02/23/2017	7					

<u>**</u>Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 25% of the shares vest on January 1, 2018 and the remainder of the shares vest in equal installments on a monthly basis thereafter, such that the option is fully vested on January 1, 2021.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.